Drug Profile
Atorvastatin/fimasartan - Boryung Pharmaceutical
Alternative Names: Akarb; Atorvastatin/BR-A 657; BR-1017B; Fimasartan/atorvastatin - Boryung PharmaceuticalLatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Boryung Pharmaceutical
- Class Antihyperlipidaemics; Antihypertensives; Fatty acids; Fluorobenzenes; Heptanoic acids; Pyrimidinones; Pyrroles; Small molecules
- Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Dyslipidaemias; Hypertension
- Phase III Essential hypertension
Most Recent Events
- 13 Jul 2023 Phase-III clinical trials in Essential hypertension (Combination-therapy) in South Korea (unspecified route) (NCT05930028)
- 10 Jul 2023 Boryung Pharmaceutical plans a phase III trial for Essential hypertension and Hypercholesterolaemia (Combination therapy) in South Korea in July 2023 (NCT05930028)
- 15 Jan 2018 Phase-III clinical trials in Hypertension and Dyslipidaemias in South Korea (PO)